3,112 results match your criteria Polymyalgia Rheumatica


Predictors of fragility fracture and low bone mineral density in patients with a history of parental fracture.

Osteoporos Sarcopenia 2019 Mar 15;5(1):6-10. Epub 2019 Mar 15.

University Hospitals of Morecambe Bay NHS Foundation Trust, Royal Lancaster Infirmary, Rheumatology, Ashton Road, Lancaster, Lancashire, UK.

Objectives: Bone mineral density (BMD) and fragility fracture (FF) have high heritability, but few data exist on impact of other factors on families with fracture history. We aimed to evaluate predictors of FF and low BMD, in patients with family history of FF.

Methods: This was a retrospective study on patients undergoing dual energy X-ray absorptiometry at a district general hospital (DGH), 2004-2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.afos.2019.03.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452922PMC

[Clinical experience of professor - in channel palpation treatment for polymyalgia rheumatica].

Zhongguo Zhen Jiu 2019 Apr;39(4):419-22

Department of Acupuncture and Moxibustion, Huguosi Chinese Medicine Hospital Affiliated to Beijing University of CM, Beijing 100035.

Professor - has gradually improved the clinical application of channel palpation treatment based on his more than 50 years clinical practice, and has accumulated rich experience in acupuncture treatment of polymyalgia rheumatica. He believes that "wind, cold and dampness" are the external causes of the disease, physical factors, uncomfortable mood and uncontrolled diet are the internal causes. The meridian-collateral theory is utilized in the diagnosis and detection of the disorders of , and meridians, internal and external causes are solved by expelling the wind, warming the channel to eliminate the coldness, transforming the dampness to relieve pain and regulating the activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.13703/j.0255-2930.2019.04.019DOI Listing
April 2019
1 Read

A Case of Polymyalgia Rheumatica Following Robotic-Assisted Radical Prostatectomy for High-Grade Prostate Cancer.

Am J Case Rep 2019 Apr 7;20:474-477. Epub 2019 Apr 7.

Internal Medicine Consult Service, Clinical Center, National Institutes of Health (NIH), Bethesda, MD, USA.

BACKGROUND Polymyalgia rheumatica (PMR) is a common rheumatic disease in patients over the age of 50 years. Underlying triggers for PMR are not well understood, but there have been reports of cases presenting prior to the diagnosis of prostate cancer, with one case of PMR presenting following prostatectomy. This report is of a case of PMR that presented following robotic-assisted radical prostatectomy for high-grade prostate cancer and includes a discussion of the possible associations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.914152DOI Listing
April 2019
1 Read

Polymyalgia rheumatica occurrence under multikinase inhibitors (sorafenib and erlotinib) treatment.

Joint Bone Spine 2019 Mar 27. Epub 2019 Mar 27.

Service de rhumatologie, CHRU de Besançon, 25030 Besançon, France; EA 4266 "pathogens and inflammation/EPILAB" université Bourgogne Franche-Comté, 25000 Besançon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbspin.2019.03.005DOI Listing
March 2019
4 Reads

The impact of temporal artery biopsy for the diagnosis of giant cell arteritis in clinical practice in a tertiary university hospital.

PLoS One 2019 29;14(3):e0210845. Epub 2019 Mar 29.

Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.

Background: Temporal artery biopsy (TAB) is useful in assisting with giant cell arteritis (GCA) diagnosis but lacks sensitivity. The aim of our study was to assess the diagnostic impact of TAB histology in patients with suspected GCA on hospital admission.

Methods: A prospectively maintained database was queried for all TABs performed between 1-1-2000 until 31-12-2017 at the University Hospital of Ioannina. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210845PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440612PMC
March 2019
2 Reads
3.234 Impact Factor

Features and prognosis of giant cell arteritis in patients over 85years of age: A case-control study.

Semin Arthritis Rheum 2019 Mar 2. Epub 2019 Mar 2.

Department of Internal Medicine, Caen University Hospital, Caen, France.

Background: We examined the initial features, course, and prognosis of giant cell arteritis (GCA) in patients ≥ 85years of age (≥85 year) and compared them to those of younger patients.

Methods: The present retrospective study included all patients who were newly diagnosed with GCA in the Internal Departments of two French University Hospitals from 1976 or 1998 to 2017 and who were followed up for at least 6 months. Logistic regression analyses were conducted to identify baseline and prognostic characteristics associated with being ≥85 year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2019.02.011DOI Listing
March 2019
1 Read

Treatment of polymyalgia rheumatica.

Biochem Pharmacol 2019 Mar 20. Epub 2019 Mar 20.

Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain; University of Cantabria, Santander, Spain; Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa. Electronic address:

Polymyalgia rheumatica (PMR) is an inflammatory disease characterized by bilateral pain involving predominantly the shoulders and proximal aspects of the arms and less commonly the neck and the pelvic girdle. This review discusses briefly the main epidemiological data and clinical features of this condition. Especial attention is paid in the management of the disease. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00062952193011
Publisher Site
http://dx.doi.org/10.1016/j.bcp.2019.03.027DOI Listing
March 2019
3 Reads

Identification of an activated neutrophil phenotype in polymyalgia rheumatica during steroid treatment: a potential involvement of immune cell cross-talk.

Clin Sci (Lond) 2019 Apr 4;133(7):839-851. Epub 2019 Apr 4.

Department of Biochemical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, U.K.

We have reported the existence of a distinct neutrophil phenotype in giant cell arteritis (GCA) patients arising at week 24 of steroid treatment. In the present study, we investigated whether longitudinal analysis of neutrophil phenotype in patients with polymyalgia rheumatica (PMR) could reveal a novel association with disease status and immune cell cross-talk. Thus, we monitored PMR patient neutrophil phenotype and plasma microvesicle (MV) profiles in blood aliquots collected pre-steroid, and then at weeks 1, 4, 12 and 24 post-steroid treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/CS20180415DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449535PMC
April 2019
2 Reads

2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis.

Ann Rheum Dis 2019 Mar 21. Epub 2019 Mar 21.

Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany.

Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis and is frequently associated with comorbidities related to the disease itself or induced by the treatment. Systematically collected data on disease course, treatment and outcomes of GCA remain scarce. The aim of this EULAR Task Force was to identify a core set of items which can easily be collected by experienced clinicians, in order to facilitate collaborative research into the course and outcomes of GCA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214755DOI Listing
March 2019
1 Read

Localized Myofascial Inflammation by Magnetic Resonance Imaging in Recent-Onset Polymyalgia Rheumatica and Effect of Tocilizumab Therapy.

J Rheumatol 2019 Mar 15. Epub 2019 Mar 15.

From the Radiology department, CHU de Brest, Brest, France; Rheumatology department, Centre National de Référence des Maladies Auto-Immunes Rares (CERAINO), CHU Brest, Brest, France; INSERM UMR 1227, Laboratoire d'Immunothérapie et Pathologies lymphocytaires B, Labex 'Immunotherapy, Graft, Oncology', Université de Brest, 29609 Brest Cedex, France. The TENOR study received an unconditional grant and the tocilizumab used for the study was donated by Roche-Chugai. Roche-Chugai had no role in the design or conduct of the TENOR study or the current study; data collection, analysis, or interpretation; or preparation, revision, or approval of the manuscript. Conflicts of interest: Alain Saraux and Valerie Devauchelle-Pensec have received consultancy fees and a grant from Roche Chugai (TENOR study). The current study was conducted in a manner entirely independent from Roche Chugai. Address correspondence to Prof. Alain Saraux, Rheumatology Unit, Hôpital de la Cavale Blanche, BP 824, F 29609 Brest cedex, France. E-mail:

Objective: To assess the prevalence of myofascial inflammatory lesions visible by magnetic resonance imaging (MRI) and their changes after tocilizumab therapy in active polymyalgia rheumatica (PMR).

Methods: We conducted a post hoc analysis of data from the TENOR study of tocilizumab monotherapy in PMR. The 18 patients each received tocilizumab injections at weeks 0, 4, and 8. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180958DOI Listing
March 2019
3 Reads

Polymyalgia Rheumatica After Herpes-Zoster.

Arch Rheumatol 2018 Dec 23;33(4):494-495. Epub 2018 Mar 23.

Department of Physical Medicine and Rehabilitation, Giresun University Prof. Dr. İlhan Özdemir Training and Research Hospital, Giresun, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5606/ArchRheumatol.2018.6859DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409168PMC
December 2018
1 Read

The changing pattern of fever of unknown origin in Republic of North Macedonia.

Rom J Intern Med 2019 Mar 11. Epub 2019 Mar 11.

University Hospital for Infectious diseases and febrile conditions, Medical Faculty "Ss Cyril and Methodius" University, Skopje, Republic of North Macedonia.

Introduction: The study aimed to compare the etiologic spectrum of diseases causing fever of unknown origin (FUO) and methods for definitive diagnosis in a tertiary care hospital in Republic of North Macedonia during two different time periods.

Patients And Methods: retrospectively were analysed the causes for FUO and final diagnostic approaches in 185 patients with classic FUO that were treated at the University Hospital for Infectious diseases in Skopje during two time periods. Seventy nine patients were treated during 1991 to 1995 and 106 patients during 2011 to 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/rjim-2019-0007DOI Listing
March 2019
2 Reads

Differences of articular and extra-articular involvement in polymyalgia rheumatica: A comparison by whole-body FDG-PET/CT.

Mod Rheumatol 2019 Mar 7:1-7. Epub 2019 Mar 7.

c Department of Radiology , Fukuoka Memorial Hospital , Fukuoka , Japan.

Objectives: To clarify differences in incidences of articular and extra-articular involvement in patients with polymyalgia rheumatica (PMR) using FDG-PET/CT.

Methods: Twenty PMR patients were enrolled in this retrospective study. We compared frequency, degree, and patterns (diffuse or non-diffuse) of abnormal FDG accumulation in the proximal and distal articular structures (PAS, DAS), and extra-articular synovial structures (ESS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14397595.2019.1591065DOI Listing
March 2019
1 Read

[Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].

Yakugaku Zasshi 2019 ;139(3):491-495

Department of Hospital Pharmacy, Kansai Medical University.

Nivolumab, an anti-programmed cell death 1 antibody, has been approved for the treatment of unresectable advanced non-small-cell lung cancer (NSCLC). Although immune-related adverse events (irAEs) such as dermatologic, digestive, endocrine, hepatic, and pulmonary toxicities are known to occur upon administration of immune checkpoint inhibitors, case reports of polymyalgia rheumatica (PMR) associated with nivolumab use are rare. We report a case of an NSCLC patient who developed PMR during treatment with nivolumab and received corticosteroids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1248/yakushi.18-00161DOI Listing
March 2019
1 Read

Letter to the editor: Comments on 'A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica'.

Eur J Cancer 2019 Apr 28;111:59-60. Epub 2019 Feb 28.

Department of Rheumatology, Austin Health, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.11.034DOI Listing
April 2019
1 Read

Immune Checkpoint Inhibitor-Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in a Patient After Treatment With Nivolumab.

J Clin Rheumatol 2019 Feb 19. Epub 2019 Feb 19.

Department of General Internal Medicine University Hospitals Leuven Herestraat 49, 3000 Leuven, Belgium

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000001012DOI Listing
February 2019
2 Reads

Toward a Core Outcome Measurement Set for Polymyalgia Rheumatica: Report from the OMERACT 2018 Special Interest Group.

J Rheumatol 2019 Feb 1. Epub 2019 Feb 1.

From the Department of Rheumatology, Austin Health; Department of Medicine, University of Melbourne, Melbourne; Rheumatology Unit, Royal Adelaide Hospital; Discipline of Medicine, The University of Adelaide, Adelaide, Australia; Department of Rheumatology, Addenbrooke's Hospital, Cambridge; Norwich Medical School, University of East Anglia, Norwich; Arthritis Research UK Primary Care Centre, Primary Care Sciences, Keele University, Keele; PMR-GCA Scotland, Dundee, Angus; PMR-GCA North East, Kibblesworth, Tyne and Wear; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR)-Leeds Biomedical Research Centre, Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, UK; Ottawa Hospital Research Institute; School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; SDG LLC, Cambridge, Massachusetts, USA. C.E. Owen, MBBS (Hons), Consultant Rheumatologist, Department of Rheumatology, Austin Health, and Department of Medicine, University of Melbourne; M. Yates, PhD, Clinical Research Fellow, Department of Rheumatology, Addenbrooke's Hospital, and Norwich Medical School, University of East Anglia; H. Twohig, MBChB, General Practitioner, Arthritis Research UK Primary Care Centre, Primary Care Sciences, Keele University; S. Muller, PhD, Senior Research Fellow, Arthritis Research UK Primary Care Centre, Primary Care Sciences, Keele University; L.M. Neill, BSc, OMERACT, Patient Research Partner, PMR-GCA Scotland; E. Harrison, BSc, OMERACT, Patient Research Partner, PMR-GCA North East; B. Shea, PhD, Senior Methodologist and Adjunct Professor, Ottawa Hospital Research Institute, and School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa; L.S. Simon, MD, Principal, SDG LLC; C.L. Hill, MD, Clinical Professor and Consultant Rheumatologist, Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, The University of Adelaide; S.L. Mackie, PhD, Associate Clinical Professor and Consultant Rheumatologist, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR-Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust. Address correspondence to C.E. Owen, Rheumatology Department, Austin Health, Repatriation Campus, Level 1, North Wing, 300 Waterdale Road, Heidelberg West VIC, Australia 3081. E-mail: Accepted for publication January 17, 2019.

Objective: To report the progress of the Outcome Measures in Rheumatology (OMERACT) Polymyalgia Rheumatica (PMR) Working Group in selecting candidate instruments for a core outcome measurement set.

Methods: A systematic literature review identified outcomes measured and instruments used in PMR studies, and a respondent survey and raw data analysis assessed their domain match and feasibility.

Results: Candidate instruments were identified for pain [visual analog scale/numerical rating scale (VAS/NRS)], stiffness (VAS/NRS and duration), and physical function (Health Assessment Questionnaire-Disability Index/modified Health Assessment Questionnaire). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181050DOI Listing
February 2019
7 Reads

Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases.

Prostate Cancer Prostatic Dis 2019 Jan 28. Epub 2019 Jan 28.

Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.

Background: Androgen deprivation therapy (ADT) has been a mainstay of treatment for advanced prostate cancer (PCa), but limited studies have been performed to investigate the association between ADT and autoimmune diseases.

Methods: We conducted a population-based nationwide cohort study of 17,168 patients newly diagnosed with PCa between 1996 and 2013 using the National Health Insurance Research Database (NHIRD) of Taiwan. Cox proportional hazards models with 1:1 propensity score-matched analysis were used to investigate the association between ADT use and the risk of autoimmune diseases. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-019-0130-9
Publisher Site
http://dx.doi.org/10.1038/s41391-019-0130-9DOI Listing
January 2019
19 Reads

Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses.

Ann Rheum Dis 2019 Jan 22. Epub 2019 Jan 22.

Department of Rheumatology, University Hospital Basel, Basel, Switzerland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214704DOI Listing
January 2019
6 Reads
10.377 Impact Factor

Hereditary Hemochromatosis Associations with Frailty, Sarcopenia and Chronic Pain: Evidence from 200,975 Older UK Biobank Participants.

J Gerontol A Biol Sci Med Sci 2019 Feb;74(3):337-342

Epidemiology and Public Health Group, University of Exeter Medical School, UK.

Background: Iron is essential for life but contributes to oxidative damage. In Northern-European ancestry populations, HFE gene C282Y mutations are relatively common (0.3%-0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/gerona/gly270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376086PMC
February 2019
5 Reads
5.416 Impact Factor

Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis.

Rheumatology (Oxford) 2019 Jan 10. Epub 2019 Jan 10.

Department of Rheumatology, Internal Medicine & Geriatrics, Pomeranian Medical University, Szczecin, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/key431DOI Listing
January 2019
5 Reads

The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series.

Autoimmun Rev 2019 Mar 11;18(3):287-292. Epub 2019 Jan 11.

Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, Pisa 56126, Italy. Electronic address:

Graves' disease (GD) and autoimmune thyroiditis (AT) are the two main clinical presentations of AITD, and their clinical hallmarks are thyrotoxicosis and hypothyroidism, respectively. GD, and AT, can be associated with other organ specific, or systemic autoimmune diseases in the same patient. However discordant results have been reported in the literature about the possible associations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2018.10.001DOI Listing
March 2019
18 Reads

Mizoribine is as Effective as Methotrexate for the Treatment of Polymyalgia Rheumatica: A Retrospective Case Series Analysis.

Arch Rheumatol 2018 Sep 15;33(3):302-308. Epub 2018 Jan 15.

St. Luke's International University, St. Luke's International Hospital, Immuno-Rheumatology Center, Tokyo, Japan.

Objectives: This study aims to evaluate the efficacy and safety of mizoribine (MZR) as a steroid-sparing agent compared to methotrexate (MTX) in the treatment of polymyalgia rheumatica in elderly patients.

Patients And Methods: Twenty-four patients (9 males, 15 females; mean age 71.7 years; range 50 to 86 years) diagnosed with polymyalgia rheumatica between April 1998 and August 2014, who received prednisone in combination with either MTX or MZR, were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5606/ArchRheumatol.2018.6418DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328222PMC
September 2018
2 Reads

Development of polymyalgia rheumatica during hospitalization and diagnosis based on history taking by physical and occupational therapists.

J Gen Fam Med 2019 Jan 4;20(1):28-30. Epub 2018 Dec 4.

Department of Medicine Mito Kyodo General Hospital University of Tsukuba Mito Ibaraki Japan.

Polymyalgia rheumatica (PMR) is frequently reported in the outpatient setting and presents with pain, morning stiffness, mild fever, and fatigue. However, the clinical course of PMR during hospitalization is unknown. We report a case of PMR that developed during hospitalization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jgf2.224DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321836PMC
January 2019
2 Reads

Examining management and research priorities in patients with polymyalgia rheumatica: a primary care questionnaire survey.

Clin Rheumatol 2019 Jan 7. Epub 2019 Jan 7.

Research Institute for Primary Care and Health Sciences, Keele University, Keele, UK.

Introduction/objectives: Polymyalgia rheumatica (PMR) is a common inflammatory disorder that is usually managed with oral glucocorticoids, which although effective can cause significant adverse events. Support group survey data suggests length of glucocorticoid treatment and managing side effects are key priority areas of management for patients. Recognising that not all patients will access patient support organisations, our objective was to identify priorities for PMR management and research among primary care PMR patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-018-04405-0DOI Listing
January 2019
3 Reads

Concomitant association of giant cell arteritis and malignancy: a multicenter retrospective case-control study.

Clin Rheumatol 2019 Jan 7. Epub 2019 Jan 7.

Department of Internal Medicine and Clinical Immunology, Normandie Univ, UNICAEN, CHU de Caen Normandie, Avenue de la Côte de Nacre, 14000, Caen, France.

Introduction: Some studies suggest that there is an increased risk of malignancies in giant cell arteritis (GCA). We aimed to describe the clinical characteristics and outcomes of GCA patients with concomitant malignancy and compare them to a GCA control group.

Method: Patients with a diagnosis of GCA and malignancy and with a maximal delay of 12 months between both diagnoses were retrospectively included in this study and compared to a control group of age-matched (3:1) patients from a multicenter cohort of GCA patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10067-018-04407-y
Publisher Site
http://dx.doi.org/10.1007/s10067-018-04407-yDOI Listing
January 2019
10 Reads

Interstitial Lung Disease in patients with Polymyalgia Rheumatica: A case series.

Respir Med Case Rep 2019 21;26:126-130. Epub 2018 Dec 21.

Regional Referral Center for Rare Lung Diseases, A. O. U. "Policlinico-Vittorio Emanuele" Dpt. of Clinical and Experimental Medicine, University of Catania, Italy.

Introduction: Severe morning stiffness with painful involvement of the girdles are often referred by patients with Interstitial Lung Disease (ILD), but the association between ILD and Polymyalgia Rheumatica (PMR) is rarely reported. The purpose of the work is to describe a series of patients classified as having PMR with ILD.

Material And Methods: We retrospectively enrolled patients with a diagnosis of PMR referred to our center during the previous year for respiratory symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmcr.2018.12.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307098PMC
December 2018
8 Reads

Glucocorticoid-Induced Osteoporosis.

N Engl J Med 2018 Dec;379(26):2547-2556

From the Yale School of Medicine, New Haven, CT (L.B.); and the University of Oklahoma Health Sciences Center, Oklahoma City (M.B.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMcp1800214DOI Listing
December 2018
3 Reads

Update on the epidemiology, risk factors, and outcomes of systemic vasculitides.

Best Pract Res Clin Rheumatol 2018 04 2;32(2):271-294. Epub 2018 Nov 2.

Department of Rheumatology, Hospital of Bruneck, Bruneck, Italy; Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria.

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and giant cell arteritis (GCA) are the most common primary systemic vasculitides of the adult population, while polymyalgia rheumatica (PMR) is a clinical syndrome often associated with GCA. Incidence and prevalence rates of AAV have been increasing in the last decades, whereas those of GCA and PMR have remained stable. The mutual interplay between environmental and genetic risk factors leading to the development of these diseases has been further analyzed in the last years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.berh.2018.09.001DOI Listing
April 2018
3 Reads

Comorbidities in polymyalgia rheumatica: a systematic review.

Arthritis Res Ther 2018 Nov 20;20(1):258. Epub 2018 Nov 20.

Arthritis Research UK Primary Care Centre, Primary Care Sciences, Keele University, Keele, ST5 5BG, UK.

Background And Aim: Comorbidities are known to exist in many rheumatological conditions. Polymyalgia rheumatica (PMR) is a common inflammatory rheumatological condition affecting older people which, prior to effective treatment, causes severe disability. Our understanding of associated comorbidities in PMR is based only on case reports or series and small cohort studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-018-1757-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247740PMC
November 2018
5 Reads

Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.

Eur J Cancer 2019 Jan 17;106:12-23. Epub 2018 Nov 17.

Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Germany. Electronic address:

Aim: To characterise clinical presentation, laboratory and histopathologic characteristics and assess the treatment and outcome of neuromuscular side-effects of checkpoint therapy.

Methods: The side-effect registry and the institutional database from ten skin cancer centres were queried for reports on myositis and neuromuscular side-effects induced by checkpoint inhibitors. In total, 38 patients treated with ipilimumab, tremelimumab, nivolumab and pembrolizumab for metastatic skin cancer were evaluated and characterised. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049183140
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2018.09.033DOI Listing
January 2019
24 Reads

Paraneoplastic Syndrome Presenting with Polymyalgia Rheumatica-like Accumulations on F-fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography.

Intern Med 2019 Mar 19;58(6):861-864. Epub 2018 Nov 19.

Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.

A 70-year-old woman presented with a fever and pain in both lower extremities and the right shoulder and right upper arm continuously for approximately 3 months. F-fluorodeoxyglucose-positron emission tomography/computed tomography (F-FDG/PET-CT) revealed the accumulation of FDG in the right shoulder, lumbar spinous processes, both ischial tuberosities, and both hips and greater trochanters, indicating polymyalgia rheumatica (PMR). In addition, upper gastrointestinal endoscopy revealed esophageal carcinoma. Read More

View Article

Download full-text PDF

Source
https://www.jstage.jst.go.jp/article/internalmedicine/advpub
Publisher Site
http://dx.doi.org/10.2169/internalmedicine.1847-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465020PMC
March 2019
14 Reads

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.

Lancet Oncol 2018 Dec 12;19(12):1579-1589. Epub 2018 Nov 12.

Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address:

Background: Immune checkpoint inhibitors (ICIs) have substantially improved clinical outcomes in multiple cancer types and are increasingly being used in early disease settings and in combinations of different immunotherapies. However, ICIs can also cause severe or fatal immune-related adverse-events (irAEs). We aimed to identify and characterise cardiovascular irAEs that are significantly associated with ICIs. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183060
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30608-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287923PMC
December 2018
15 Reads

Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.

Eur J Cancer 2018 Dec 13;105:88-102. Epub 2018 Nov 13.

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department, University of Melbourne, Melbourne, Australia. Electronic address:

Importance: Rheumatic immune-related adverse events (irAEs) occur in approximately 10-20% of anti-programmed death 1 (anti-PD1)-treated cancer patients. There are limited data on the natural history, optimal treatment and long-term oncological outcomes of patients with rheumatic irAEs.

Objective: The objective of the study was to describe the spectrum and natural history of rheumatic irAEs and the potential impact of rheumatic irAEs and immunomodulators on anti-PD1 tumour efficacy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049183139
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2018.09.027DOI Listing
December 2018
23 Reads

Does low risk of infections as a marker of effective immunity predict increased risk of subsequent giant cell arteritis or polymyalgia rheumatica? A Danish population-based case-control study.

Clin Epidemiol 2018 16;10:1533-1543. Epub 2018 Oct 16.

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark,

Objective: It has been suggested that a hyper-effective immune system ("hyper-immunity") is central to the pathogenesis of giant cell arteritis and polymyalgia rheumatica (GCA/PMR). We examined if a low risk of infections, as a marker of hyper-immunity, can predict increased subsequent risk of GCA/PMR.

Patients And Methods: We conducted a population-based case-control study including all patients aged ≥50 years with incident GCA/PMR diagnosed between 1997 and 2012 in Northern Denmark. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/does-low-risk-of-infections-as-a-m
Publisher Site
http://dx.doi.org/10.2147/CLEP.S158293DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201992PMC
October 2018
17 Reads

[Glucocorticoid sensitive bilateral leg swelling in an 85-year-old woman presenting with polymyalgia rheumatica: A case report].

Rev Med Interne 2019 May 31;40(5):330-333. Epub 2018 Oct 31.

Service de rhumatologie, centre hospitalier René-Dubos, 6, avenue de l'Île-de-France, 95301 Pontoise, France. Electronic address:

Introduction: Polymyalgia rheumatica (PMR) can be associated with distal swelling indicating an associated RS3PE syndrome. We report a case of PMR associated with oedema of the lower limbs, which resolved rapidly under glucocorticoid therapy.

Case Report: A 85-year-old woman presented with a 4 month history of PMR responding to the 2012 EULAR/ACR classification criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.revmed.2018.10.004DOI Listing
May 2019
4 Reads

Permanent Discontinuation of Glucocorticoids in Polymyalgia Rheumatica Is Uncommon but May Be Enhanced by Amino Bisphosphonates.

J Rheumatol 2019 Mar 1;46(3):318-322. Epub 2018 Nov 1.

From the Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy.

Objective: The duration of treatment with glucocorticoids (GC) in polymyalgia rheumatica (PMR) is often longterm. Amino bisphosphonates (N-BP) are used in PMR for the prevention of GC-induced osteoporosis, but they coulsd also have immunomodulatory properties. Whether they can be effective as an adjuvant treatment in PMR is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180324DOI Listing
March 2019
4 Reads

Incidence of inflammatory polyarthritis in polymyalgia rheumatica: a population-based cohort study.

Ann Rheum Dis 2019 May 26;78(5):704-705. Epub 2018 Oct 26.

Norwich Medical School, Bob Champion Research and Education Building, University of East Anglia, Norwich, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214386DOI Listing
May 2019
4 Reads

Corticosteroid Tapering Regimens in Rheumatic Disease: A Systematic Review.

J Clin Rheumatol 2018 Oct 23. Epub 2018 Oct 23.

Background/objective: Corticosteroids have long been used to effectively treat rheumatic disorders, but adverse effects associated with extended-duration regimens generate disagreement among clinicians regarding optimal tapering strategies. The objective of this systematic review was to assess clinical outcomes of differing tapering regimens after corticosteroid monotherapy in adults with rheumatic disorders.

Methods: A systematic review of Medline/PubMed, Embase, Cochrane, International Pharmaceutical Abstracts, Web of Science, Scopus, Global Index Medicus, American College of Rheumatology, gray literature, and reference lists up to June 27, 2018, was conducted by 2 authors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000917DOI Listing
October 2018
18 Reads

Challenges of diagnosing and managing polymyalgia rheumatica: a multi-methods study in UK general practice.

Br J Gen Pract 2018 Nov;68(676):e783-e793

Institute for Primary Care and Health Sciences, NIHR research professor in general practice, NIHR CLAHRC West Midlands, deputy director, NIHR School for Primary Care Research, and training lead, Arthritis Research UK Primary Care Centre, Primary Care Sciences, Keele University, Keele.

Background: Polymyalgia rheumatica (PMR) is one of the most common inflammatory arthritic disorders seen in older individuals. Most patients with PMR are diagnosed and managed exclusively in general practice, yet primary care-focused research is lacking.

Aim: To identify and explore the challenges of diagnosis and management of PMR in general practice. Read More

View Article

Download full-text PDF

Source
http://bjgp.org/lookup/doi/10.3399/bjgp18X699557
Publisher Site
http://dx.doi.org/10.3399/bjgp18X699557DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193770PMC
November 2018
23 Reads

Swollen joints and peripheral arthritis are signs of malignancy in polymyalgia rheumatica.

Mod Rheumatol 2018 Dec 18:1-4. Epub 2018 Dec 18.

h Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences , Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan.

Aim: To analyze the clinical course and prognosis in patients diagnosed with polymyalgia rheumatica (PMR) complicated by the presence of malignancies.

Methods: We retrospectively screened the case files of 216 patients hospitalized in our department between 2011 and December 2016 for the results of a thorough physical examination and data on treatment for rheumatic diseases. We identified 53 patients with PMR according to Bird's criteria and 43 patients with 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for PMR, then analyzed the clinical and serologic manifestations of PMR in patients with (n = 6) and without (n = 47 in Bird' criteria, n = 37 in 2012 EULAR/ACR criteria) malignancy. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14397595.2018.1
Publisher Site
http://dx.doi.org/10.1080/14397595.2018.1538027DOI Listing
December 2018
18 Reads

Applications of PET Imaging in the Evaluation of Musculoskeletal Diseases Among the Geriatric Population.

Semin Nucl Med 2018 Nov 6;48(6):525-534. Epub 2018 Aug 6.

Department of Radiology, Hospital of University of Pennsylvania, Philadelphia, PA. Electronic address:

Medical imaging plays a particularly important role in the care of elderly patients, in whom complex symptomatology and a high prevalence of musculoskeletal diseases necessitate sensitive imaging modalities. MRI is the most commonly used imaging modality in the evaluation of various musculoskeletal disorders. The integration of positron emission technique and computed tomography as well as magnetic resonance imaging allows for generating complimentary data for accurate and quantitative diagnosis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00012998183005
Publisher Site
http://dx.doi.org/10.1053/j.semnuclmed.2018.07.002DOI Listing
November 2018
19 Reads

A Comparative Study of Doppler Ultrasound against Temporary Artery Biopsy in the Diagnosis of Giant Cell Arteritis.

Reumatol Clin 2018 Oct 11. Epub 2018 Oct 11.

Servicio de Reumatología, Complexo Hospitalario Universitario de A Coruña, La Coruña, España.

Background: Giant cell arteritis (GCA) is a vasculitis that affects medium- and large-sized arteries. Temporal artery biopsy is the gold standard for diagnosis. In view of the high demand for temporal biopsies, the purpose of this study is to evaluate the usefulness of Doppler ultrasonography in patients with suspected giant cell arteritis, to determine its sensitivity and specificity as a diagnostic test and to determine whether it would be possible to substitute biopsy for ultrasonography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.reuma.2018.08.007DOI Listing
October 2018
3 Reads

Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study.

Ann Rheum Dis 2018 Dec 8;77(12):1750-1756. Epub 2018 Oct 8.

Arthritis UK Primary Care Centre, Keele University, Keele, UK.

Objective: Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in older people. Contemporary estimates of the incidence and prevalence are lacking, and no previous study has assessed treatment patterns at a population level. This study aims to address this. Read More

View Article

Download full-text PDF

Source
http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2018-21388
Publisher Site
http://dx.doi.org/10.1136/annrheumdis-2018-213883DOI Listing
December 2018
5 Reads

Use of contrast-enhanced magnetic resonance imaging of the pelvis to describe changes at different anatomic sites which are potentially specific for polymyalgia rheumatica.

Clin Exp Rheumatol 2018 Sep-Oct;36 Suppl 114(5):86-95. Epub 2018 Oct 1.

Rheumazentrum Ruhrgebiet, Herne, Germany.

Objectives: To identify inflammatory pelvic structures of patients with polymyalgia rheumatica (PMR) by magnetic resonance imaging (MRI) in detail, searching for a disease-specific pattern.

Methods: A total of 40 contrast-enhanced pelvic MRIs of patients with a clinical diagnosis of PMR was reviewed by an experienced musculoskeletal radiologist who assessed all abnormalities semi-quantitatively, based on a predefined scoring system.

Results: The median (25th/75th percentiles) age of patients was 67 (55/73) years, median symptom duration 13 (6/22) weeks, 55% female, median CRP 1. Read More

View Article

Download full-text PDF

Source
January 2019
12 Reads

A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica.

Eur J Cancer 2018 Nov 1;103:281-283. Epub 2018 Oct 1.

Department of Internal Medicine, Nîmes University Hospital, Nîmes, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049183133
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2018.07.318DOI Listing
November 2018
7 Reads

Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients.

Arthritis Rheumatol 2019 Mar 28;71(3):468-475. Epub 2019 Jan 28.

Mayo Clinic, Rochester, Minnesota.

Objective: To describe the prevalence, clinical presentation, and management of rheumatic immune-related adverse effects (Rh-irAEs) from immune checkpoint inhibitor (ICI) therapy.

Methods: From a database of all patients who received any ICI at the Mayo Clinic Rochester, Minnesota campus between January 1, 2011 and March 1, 2018, we retrospectively identified those with Rh-irAEs, using diagnostic codes, search terms, and manual chart review.

Results: Of the 1,293 patients who received any ICI, Rh-irAEs were clinically diagnosed in 43. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.40745DOI Listing
March 2019
2 Reads

Cross-sectional survey of the undergraduate rheumatology curriculum in European medical schools: a EULAR School of Rheumatology initiative.

RMD Open 2018 21;4(2):e000743. Epub 2018 Sep 21.

Université Paris Diderot, USPC, UFR de Médecine, Paris, France.

Objectives: To survey the undergraduate rheumatic and musculoskeletal diseases (RMDs) curriculum content in a sample of medical schools across Europe.

Methods: The undergraduate musculoskeletal diseases and disability curriculum of University of Nottingham, UK, was used as a template to develop a questionnaire on curriculum content. The questionnaire elicited binary (yes/no) responses and included the option to provide additional information as free text. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2018-000743DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157535PMC
September 2018
12 Reads

[Improved early diagnostics of rheumatic diseases : Monocentric experiences with an open rheumatological specialist consultation].

Z Rheumatol 2018 Nov;77(9):844-849

Standort Berlin Buch, Immanuel Krankenhaus Berlin, Lindenberger Weg 19, 13125, Berlin, Deutschland.

Aim Of The Project: To establish an open rheumatological outpatient consultation service for early diagnosis of inflammatory rheumatic diseases and initiation of further diagnostics and treatment.

Methods: In 2015 an open consultation service was initiated for patients with signs of an early rheumatic disease after referral by primary care physicians. Patients could attend once a week without the need for a prior appointment if they fulfilled at least one of the following criteria: positive rheumatoid factor, increased CRP, anti-CCP antibody or antinuclear antibody, joint pain or back pain for over 3 months, swollen joints, fever of unknown origin or acute muscle pain with or without headache of unknown origin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00393-018-0540-4DOI Listing
November 2018
3 Reads